Kidney Cancer

“After 28 months’ follow-up, the combination of pembrolizumab and belzutifan resulted in a statistically significant and clinically meaningful improvement in disease-free survival over pembrolizumab single agent,” said Toni K. Choueiri, MD.

Bourlon outlines what to watch for in prostate, urothelial, kidney, and testicular cancer.

Adam B. Weiner, MD, is joined by Brian M. Shuch, MD, for a concise yet wide-ranging update on the evolving role of adjuvant therapy in renal cell carcinoma.

The study is designed to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of NEO-811 in clear cell renal cell carcinoma.

A recap of the FDA submissions and regulatory decisions in urology from November 2025.

[68Ga]Ga-DPI-4452 is a gallum-68-radiolabeled PET imaging agent that forms a theranostic pair with the therapeutic candidate, [177Lu]Lu-DPI-4452 (ITM-91).

Mobley also shares her treatment approach to BPH and explains the challenges of treating OAB.

Merck plans to share these data with regulatory authorities worldwide.

The phase 3 LITESPARK-011 trial has met its primary end point.

Data indicates that the DFS improvement was largely driven by the treatment effect in the higher risk population.

The median progression-free survival was 15.7 months with the combination of lenvatinib plus everolimus compared with 10.2 months with cabozantinib (HR, 0.51; 95% CI, 0.29-0.89; P = .02).

"Observed efficacy of pembrolizumab plus lenvatinib were confirmatory of prior observations for this combination," said Cristina Suarez Rodriguez, MD, PhD.

Andrew W. Hahn, MD, details phase 2 efficacy findings on lenvatinib plus everolimus vs cabozantinib in patients with metastatic ccRCC.

Data from the ARC-20 trial show promising efficacy and a manageable safety profile for casdatifan monotherapy.

Here’s a look back at notable news between July and September 2025.

This clearance adds onto a previous indication for the BioTraceIO platform in liver tumor ablation.

The combination also yielded durable responses in a subset of patients with sporadic papillary renal cell carcinoma.

Daniel Canter, MD, shares his thoughts on the potential impact of 89Zr-girentuximab for kidney cancer management, if approved.

Singer reflects on how clinical trial design, patient selection, and biomarker research are driving more individualized therapy choices.

Take a look through key stories from last month, including regulatory news, trial updates, and other practice-changing advancements.

Five-year data from the phase 3 KEYNOTE-426 trial confirm the clinical benefits of front-line pembrolizumab plus axitinib in advanced ccRCC.

Sonam Saxena discusses recent findings on trends in surgery vs active surveillance for localized kidney cancer.

MRWS was shown to prolong the time off systemic therapy and was associated with favorable tolerability.

A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.

One key approach is to increase the representation of women on editorial boards of journals and as reviewers.